Testing drugs already authorized in humans, which we have good reason to believe will be effective in Covid-19: the approach is attractive as it seems to promise savings in time and money.
With a new molecule, about fifteen years can elapse between the validation of the pharmacological hypothesis and the arrival of the product on the market.
Develop the drug, test its efficacy and toxicity in animals and then, in careful stages, in humans ...
To discover
Covid-19: what we know about the Delta variant
The repositioning of already known molecules exempts researchers from many of these long and tedious steps, and never have the attempts been as numerous as during the emergency of the start of the Covid-19 pandemic.
Several thousand molecules have thus been tested and many have shown positive results
in vitro
… before struggling to transform the test
in vivo
.
Read also:
Contagiousness, immunity, dangerousness: should we be afraid of the Delta variant?
Among the many works launched around the world, an international collaboration bringing together the University
This article is for subscribers only.
You have 79% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in